CN105412511A - Medicine composition for treating prostatitis - Google Patents
Medicine composition for treating prostatitis Download PDFInfo
- Publication number
- CN105412511A CN105412511A CN201510988911.4A CN201510988911A CN105412511A CN 105412511 A CN105412511 A CN 105412511A CN 201510988911 A CN201510988911 A CN 201510988911A CN 105412511 A CN105412511 A CN 105412511A
- Authority
- CN
- China
- Prior art keywords
- parts
- pharmaceutical composition
- prostatitis
- group
- rat
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/282—Artemisia, e.g. wormwood or sagebrush
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/68—Plantaginaceae (Plantain Family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/756—Phellodendron, e.g. corktree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
- A61K36/804—Rehmannia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/894—Dioscoreaceae (Yam family)
- A61K36/8945—Dioscorea, e.g. yam, Chinese yam or water yam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/90—Smilacaceae (Catbrier family), e.g. greenbrier or sarsaparilla
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- Medical Informatics (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a medicine composition for treating prostatitis, and belongs to the technical field of traditional Chinese medicine. The medicine composition is prepared from folium artemisiae argyi, astragalus membranaceus, golden cypress, dried rehamnnia roots, belvedere fruits, rhizoma smilacis glabrae, rainbow conk, akebiaquinata, plantain herb, Chinese yam and liquorice. According to the medicine composition, the total number of leukocytes in non-bacterial or bacterial prostatic fluid of a rat can be effectively decreased, the density of lecithin bodies in the prostatic fluid of the rat is increased, the wet weight coefficient of the rat gland is decreased, and the remarkable treatment effect on the prostatitis is achieved. The medicine composition further has the effects of clearing away heat and toxic materials and the like, and rehabilitation of a patient suffering from the prostatitis is facilitated.
Description
Technical field
The invention belongs to technical field of Chinese medicines, particularly relate to one and treat prostatitic pharmaceutical composition.
Background technology
Prostatitis belongs to the category such as " stranguria ", " difficulty in urination " in the traditional Chinese medical science, and its cause of disease is complicated, and symptom is various, is characterized in that the state of an illness is prolonged to move, pathogen usually intruding into collateral in protracted disease, and venation is not smooth, stagnation of QI-blood, and prolonged illness must be empty.Theoretical from Chinese medical discrimination, the Etiological pathogenesis of prostatitis and prostatic hyperplasia is deficiency of kidney-essence, qi depression to blood stasis, pyretic toxicity pent up and caused by damp invasion of lower energizer, should regulate the flow of vital energy with the kidney invigorating during treatment, activating blood circulation to dissipate blood stasis, heat-clearing and toxic substances removing, inducing diuresis for treating stranguria syndrome, reach the object for the treatment of both the principal and the secondary aspects of a disease at the same time.Adopt Chinese medicine prostatitis, have flexibly dialectical, exchange prescription degree of freedom large, due to illness treat, because people treats, treating both the principal and secondary aspects of a disease, does not recur more, the object that reaching effects a permanent cure digs up the roots and advantage.
Western medical treatment treatment prostatitis mainly adopts antibacterial therapy, takes antiinflammatory, analgesic, naturopathy and therapeutic method of surgery.And in prostatitic treatment with western, repeatedly can use broad ectrum antibiotic in a large number, thus cause dysbacteriosis in body, immunity degradation, make non-pathogenic pathogen, fungus, microorganism amount reproduction originally, become the root of bringing out new infection or increasing the weight of original infection.The side effect of western medicine prostatitis is large, DeGrain.For avoiding prostatitis patient to bear cureless huge mental pressure and mental burden, treatment by Chinese herbs method is taked to be to take stopgap measures the preferred approach of effecting a permanent cure to prostatitis.
Chinese patent application 00113975.4 discloses one and treats prostatitic medicine, and this medicine is obtained by following raw material: Herba Taraxaci, Herba Violae, Rhizoma Smilacis Glabrae, Spina Gleditsiae, Rhizoma Curcumae, Herba Leonuri, HUANGLONG seven, Semen Abutili, the Radix Pulsatillae, white portion, Radix Platycodonis and Radix Glycyrrhizae.This medicine has curative effect in treatment chronic prostatitis, but this Drug therapy prostatitic cycle is long, and curative effect is not very remarkable in anti-inflammatory analgetic.
Summary of the invention
The technical problem to be solved in the present invention is to provide one and treats prostatitic pharmaceutical composition, and this pharmaceutical composition is row adenitis aspect before the treatment, pointed strong, advantage that good effect, relapse rate are low.Meanwhile, the present invention also provides its preparation technology.
One treats prostatitic pharmaceutical composition, is made up of the raw material of following parts by weight: Folium Artemisiae Argyi 10-25 part, Radix Astragali 9-20 part, Cortex Phellodendri 8-15 part, Radix Rehmanniae 8-15 part, Fructus Kochiae 3-10 part, Rhizoma Smilacis Glabrae 6-12 part, Coriolous Dersicolor (Fr.) Quel 6-12 part, Caulis Akebiae 3-8 part, Herba Plantaginis 3-6 part, Rhizoma Dioscoreae 2-6 part and Radix Glycyrrhizae 1-10 part.
Preferably, described pharmaceutical composition is made up of the raw material of following parts by weight: Folium Artemisiae Argyi 10 parts, the Radix Astragali 9 parts, Cortex Phellodendri 8 parts, Radix Rehmanniae 8 parts, the Fructus Kochiae 3 parts, Rhizoma Smilacis Glabrae 6 parts, Coriolous Dersicolor (Fr.) Quel 6 parts, Caulis Akebiae 3 parts, Herba Plantaginis 3 parts, Rhizoma Dioscoreae 2 parts and 1 part, Radix Glycyrrhizae.
Preferably, described pharmaceutical composition is made up of the raw material of following parts by weight: Folium Artemisiae Argyi 20 parts, the Radix Astragali 15 parts, Cortex Phellodendri 12 parts, Radix Rehmanniae 12 parts, the Fructus Kochiae 6 parts, Rhizoma Smilacis Glabrae 9 parts, Coriolous Dersicolor (Fr.) Quel 9 parts, Caulis Akebiae 6 parts, Herba Plantaginis 4 parts, Rhizoma Dioscoreae 4 parts and 5 parts, Radix Glycyrrhizae.
Preferably, described pharmaceutical composition is made up of the raw material of following parts by weight: Folium Artemisiae Argyi 25 parts, the Radix Astragali 20 parts, Cortex Phellodendri 15 parts, Radix Rehmanniae 15 parts, the Fructus Kochiae 10 parts, Rhizoma Smilacis Glabrae 12 parts, Coriolous Dersicolor (Fr.) Quel 12 parts, Caulis Akebiae 8 parts, Herba Plantaginis 6 parts, Rhizoma Dioscoreae 6 parts and 10 parts, Radix Glycyrrhizae.
Preferably, described pharmaceutical composition is made into capsule, tablet, powder or granule.
Correspondingly, present invention also offers the preparation method of the prostatitic pharmaceutical composition of described treatment, the preparation method of described pharmaceutical composition comprises the steps:
(1): get Folium Artemisiae Argyi, clean dry is ground into coarse powder, be placed in supercritical carbon dioxide extraction apparatus, the 35-50% volume fraction adding described coarse powder weight is the ethanol of 75-85%, and regulation and control carbon dioxide flow is 15-20L/h, and extracting pressure is 15-20MPa, extraction temperature is 45-60 DEG C, extraction time is 1.5-2h, and decompression separation obtains Folium Artemisiae Argyi extractive liquid, retains Folium Artemisiae Argyi residue;
(2): get the Radix Astragali, Cortex Phellodendri, Radix Rehmanniae, the Fructus Kochiae, Rhizoma Smilacis Glabrae, Coriolous Dersicolor (Fr.) Quel, Caulis Akebiae, Herba Plantaginis, Rhizoma Dioscoreae and Radix Glycyrrhizae, add above-mentioned Folium Artemisiae Argyi residue, add the distilled water immersion 2-4 hour of medical material total amount 3-6 times weight, boil 3-5 hour, filter, obtain filtrate and filtering residue, the purified water of initial medical material 3-5 times weight is added in filtering residue, boil 1-3 hour, filtration obtains filtrate and preserves filtering residue, merges twice filtrate, concentrated, obtaining detecting relative density at 65 DEG C is the extractum A of 1.20-1.30, for subsequent use;
(3): the ethanol adding the concentration 65-80% of 3-7 times of weight in the filtering residue of (2), reflux, extract, 1-2 time, each 3-7 hour, filters, merging filtrate, and distilling under reduced pressure removing ethanol is also concentrated, obtains the extractum B that 65 DEG C of relative densities are 1.20-1.30, for subsequent use;
(4); Merge described extractum A, described extractum B and described Folium Artemisiae Argyi extractive liquid, concentrating under reduced pressure, obtaining 65 DEG C of relative densities is the extractum of 1.20-1.30, to obtain final product.
Source, the nature and flavor of the present invention's component used, return through and effect:
Folium Artemisiae Argyi: this product is the dried leaves of feverfew Chinese mugwort; Acrid in the mouth, hardship, warm in nature; Return liver,spleen,kidney warp; Dispersing cold for relieving pain, warming the meridian for stopping bleeding.
The Radix Astragali: this product is the root of the leguminous plant Radix Astragali; Sweet in the mouth, tepor; Return lung, spleen, liver, kidney channel; Invigorating QI to consolidate the body surface resistance, expelling pus and toxin by strengthening QI, diuresis, granulation promoting.
Cortex Phellodendri: this product is the dry bark of rutaceae wampee or Cortex Phellodendri; Bitter in the mouth, cold in nature; Return kidney, urinary bladder channel; Heat clearing away, dampness, pathogenic fire purging, removing toxic substances.
Radix Rehmanniae: this product is the tuber of scrophulariaceae rehmannia glutinosa plant; Sweetness and bitterness, cool in nature; Enter the heart, liver, kidney channel; Heat clearing away, YIN nourishing of promoting the production of body fluid, nourishes blood.
The Fructus Kochiae: this product is the dry mature fruit of chenopod Fructus Kochiae; Acrid in the mouth, hardship; Cold in nature; Return kidney, urinary bladder channel; Clearing away heat-damp and promoting diuresis, dispelling wind for relieving itching.
Rhizoma Smilacis Glabrae: this product is the dry rhizome of liliaceous plant smilacis glabra; Sweet in the mouth, light, property is put down; Return liver, stomach warp; Dehumidifying, removing toxic substances, easing joint movement.
Coriolous Dersicolor (Fr.) Quel: this product is the dry sporophore of Polyporaceae Trametes; Sweet in the mouth, light; Cold nature; Return liver, spleen channel; Heat clearing away, removing toxic substances, antiinflammatory, anticancer, protect the liver.
Caulis Akebiae: this product is the woody stems of plants of Lardizabalaceae Caulis Akebiae or threeleaf akebia, Caulis Akebiae; Bitter in the mouth, cool in nature; Enter the heart, small intestinal, urinary bladder channel; Pathogenic fire purging row water, promoting blood circulation.
Herba Plantaginis: this product is the dry herb of Plantaginaceae plant Herba Plantaginis or Plantago depressa Willd; Sweet in the mouth, cold in nature; Return liver, kidney, lung, small intestine meridian; Clearing away heat and promoting diuresis, eliminates the phlegm, removing heat from blood, removing toxic substances.
Rhizoma Dioscoreae: this product is the dry rhizome of Dioscoreaceae plant Rhizoma Dioscoreae; Sweet in the mouth is flat; Return spleen, lung, kidney channel; Spleen reinforcing nourishing the stomach, promote the production of body fluid lung benefiting, the kidney invigorating arresting seminal emission.
Radix Glycyrrhizae: this product is the dry root of glycyrrhizic legume, Glycyrrhiza inflata Bat. or Glycyrrhiza glabra L.; Sweet in the mouth, property is put down; GUIXIN, lung, spleen, stomach warp; Invigorating the spleen and replenishing QI, heat-clearing and toxic substances removing, expelling phlegm for arresting cough, relieving spasm to stop pain, coordinating the actions of various ingredients in a prescription.
Pharmaceutical composition of the present invention with Folium Artemisiae Argyi and the Radix Astragali for monarch drug, dispersing cold for relieving pain, expelling pus and toxin by strengthening QI, diuresis, granulation promoting; With Cortex Phellodendri, Radix Rehmanniae, the Fructus Kochiae and Rhizoma Smilacis Glabrae for ministerial drug, heat clearing and damp drying, dispelling wind for relieving itching, eliminating fire and detoxication; With Coriolous Dersicolor (Fr.) Quel, Caulis Akebiae and Herba Plantaginis for adjuvant drug, spleen reinforcing nourishing the stomach, promote the production of body fluid lung benefiting, the kidney invigorating arresting seminal emission; With Rhizoma Dioscoreae and Radix Glycyrrhizae for making medicine, the coordinating the actions of various ingredients in a prescription property of medicine, all medicines coordinate, and complement each other, synergism, plays heat clearing and damp drying altogether, eliminating fire and detoxication, effects such as lung benefiting, anti-inflammatory analgetic of promoting the production of body fluid, and have very significant curative effect to treatment prostatitis.
Compared with prior art, the present invention has following technical advantage:
1, results of animal display, pharmaceutical composition of the present invention can effectively reduce total white blood cells in rat non-bacterial or bacillary prostatic fluid, increase the lecithin density in rat prostate liquid, obviously can also reduce rat prostate siphonal lobe weight in wet base coefficient, visible, pharmaceutical composition of the present invention all has inhibitory action to prostatitis rat and benign prostatic hyperplasia in rats;
2, pharmaceutical composition of the present invention is natural pure pharmaceutical composition, and toxic and side effects is little, also has effect of heat-clearing and toxic substances removing, to prostatitis treating successful, stablize, and treatment cycle is short, relapse rate is low.
Therefore, the present invention's also application of claimed aforementioned pharmaceutical compositions in the prostatitic medicine of preparation treatment.
Detailed description of the invention
It will be understood by those skilled in the art that technology disclosed in following examples represents the technology playing good action in the practice of the invention of the present inventor's discovery.But, many changes can be made in disclosed specific embodiments, and still obtain same or analogous result, and not depart from the spirit and scope of the present invention.
embodiment 1:
The embodiment of the present invention 1 pharmaceutical composition is made up of the raw material of following parts by weight: Folium Artemisiae Argyi 10 parts, the Radix Astragali 9 parts, Cortex Phellodendri 8 parts, Radix Rehmanniae 8 parts, the Fructus Kochiae 3 parts, Rhizoma Smilacis Glabrae 6 parts, Coriolous Dersicolor (Fr.) Quel 6 parts, Caulis Akebiae 3 parts, Herba Plantaginis 3 parts, Rhizoma Dioscoreae 2 parts and 1 part, Radix Glycyrrhizae.
Preparation method is as follows:
(1): get Folium Artemisiae Argyi, clean dry is ground into coarse powder, be placed in supercritical carbon dioxide extraction apparatus, 40% volume fraction adding described coarse powder weight is the ethanol of 75%, and regulation and control carbon dioxide flow is 15L/h, and extracting pressure is 15MPa, extraction temperature is 50 DEG C, extraction time is 1.5h, and decompression separation obtains Folium Artemisiae Argyi extractive liquid, retains Folium Artemisiae Argyi residue;
(2): get the Radix Astragali, Cortex Phellodendri, Radix Rehmanniae, the Fructus Kochiae, Rhizoma Smilacis Glabrae, Coriolous Dersicolor (Fr.) Quel, Caulis Akebiae, Herba Plantaginis, Rhizoma Dioscoreae and Radix Glycyrrhizae, add above-mentioned Folium Artemisiae Argyi residue, add the distilled water immersion 3 hours of medical material total amount 4 times of weight, boil 4 hours, filter, obtain filtrate and filtering residue, in filtering residue, add the purified water of initial medical material 4 times of weight, boil 2 hours, filtration obtains filtrate and preserves filtering residue, merges twice filtrate, concentrated, obtaining detecting relative density at 65 DEG C is the extractum A of 1.25, for subsequent use;
(3): the ethanol adding the concentration 75% of 5 times of weight in the filtering residue of (2), reflux, extract, 2 times, each 5 hours, filters, merging filtrate, and distilling under reduced pressure removing ethanol is also concentrated, obtains the extractum B that 65 DEG C of relative densities are 1.25, for subsequent use;
(4); Merge described extractum A, described extractum B and described Folium Artemisiae Argyi extractive liquid, concentrating under reduced pressure, obtaining 65 DEG C of relative densities is the extractum of 1.25, to obtain final product.
embodiment 2
The embodiment of the present invention 2 pharmaceutical composition is made up of the raw material of following parts by weight: Folium Artemisiae Argyi 20 parts, the Radix Astragali 15 parts, Cortex Phellodendri 12 parts, Radix Rehmanniae 12 parts, the Fructus Kochiae 6 parts, Rhizoma Smilacis Glabrae 9 parts, Coriolous Dersicolor (Fr.) Quel 9 parts, Caulis Akebiae 6 parts, Herba Plantaginis 4 parts, Rhizoma Dioscoreae 4 parts and 5 parts, Radix Glycyrrhizae.
Preparation method is with embodiment 1.
embodiment 3:
The embodiment of the present invention 3 pharmaceutical composition is made up of the raw material of following parts by weight: Folium Artemisiae Argyi 25 parts, the Radix Astragali 20 parts, Cortex Phellodendri 15 parts, Radix Rehmanniae 15 parts, the Fructus Kochiae 10 parts, Rhizoma Smilacis Glabrae 12 parts, Coriolous Dersicolor (Fr.) Quel 12 parts, Caulis Akebiae 8 parts, Herba Plantaginis 6 parts, Rhizoma Dioscoreae 6 parts and 10 parts, Radix Glycyrrhizae.
Preparation method is with embodiment 1.
pharmaceutical composition of the present invention is to the research experiment of prostatitis rat
1, pharmaceutical composition of the present invention is on the impact of rat nonbacterial prostatitis
Get healthy male Wistar rat 20, prostatitis male Wistar rat 160, body weight 170-220g, 20 healthy male Wistar rats are blank group, 160 prostatitis male Wistar rats are divided into 8 groups at random, often organizing 20, is model group, high dose 1 group, middle dosage 1 group, low dosage 1 group, high dose 2 groups, middle dosage 2 groups, low dosage 2 groups and positive controls.Wherein blank group, model group are to the distilled water of equivalent; High dose 1 group, middle dosage 1 group, low dosage 1 group be the high, medium and low dosage of pharmaceutical composition for preparing of the gavage embodiment of the present invention 1 respectively; High dose 2 groups, middle dosage 2 groups, low dosage 2 groups be the high, medium and low dosage of pharmaceutical composition for preparing of the gavage embodiment of the present invention 2 respectively; (Beijing Kangdini Pharmaceutical Co., Ltd. produces positive controls gavage Qianlieshu pill, the accurate word Z10910009 of traditional Chinese medicines), dosage in table 1, every day 1 time, after administration on the 7th, each group of rat is anaesthetized, after routine disinfection, cuts abdominal cavity open, to the sterile saline of blank group rat prostate siphonal lobe injection equivalent, all the other respectively group rats inject sterilizing ear XIAOZHILING ZHUSHEYE respectively, then layer-by-layer suture, then continue gastric infusion and amount to 20 days.After last administration 30min, put to death each treated animal, win prostate, massotherapy gets 10 μ l prostatic fluid, counts leukocyte count under the microscope, separately gets prostatic fluid smear, Microscopic observation lecithin density.Experimental result is in table 1, table 2.
Table 1 pharmaceutical composition of the present invention is on the impact of nonbacterial prostatitis rat model total white blood cells
Note: compare with blank group,
#p<0.05,
##p<0.01; Compare with model group,
△ p<0.05,
△ △ p<0.01, compares with positive controls, * P<0.05.
Table 2 pharmaceutical composition of the present invention is on the impact of the lecithin density of prostatitis rat
Note: compare with blank group,
#p<0.05,
##p<0.01; Compare with model group,
△ p<0.05,
△ △ p<0.01, compares with positive controls, * P<0.05.
As can be seen from Table 1, contrast with model group, the total white blood cells of the high, medium and low dosage group of pharmaceutical composition of the present invention significantly reduces, and model group compares the change (P<0.01) with pole significance; High dose group and low dose group have the change (P<0.05) of significance compared with positive controls.
As can be seen from Table 2, contrast with model group, the lecithin density of the prostatitis rat of the high, medium and low dosage group of pharmaceutical composition of the present invention significantly increases, and model group compares the change (P<0.01) with pole significance; High dose group and low dose group have the change (P<0.05) of significance compared with positive controls, illustrate that Chinese medicine composition of the present invention can effectively reduce total white blood cells and the lecithin density increased in rat prostate liquid in rat non-bacterial prostatic fluid.
2, pharmaceutical composition of the present invention is on the impact of rat bacterial prostatitis
Get healthy male Wistar rat 20, prostatitis male Wistar rat 160, body weight 150-220g, 20 healthy male Wistar rats are blank group, 160 prostatitis male Wistar rats are divided into 8 groups at random, often organizing 20, is model group, high dose 1 group, middle dosage 1 group, low dosage 1 group, high dose 2 groups, middle dosage 2 groups, low dosage 2 groups and positive controls.Wherein blank group, model group are to the distilled water of equivalent; High dose 1 group, middle dosage 1 group, low dosage 1 group be the high, medium and low dosage of pharmaceutical composition for preparing of the gavage embodiment of the present invention 1 respectively; High dose 2 groups, middle dosage 2 groups, low dosage 2 groups be the high, medium and low dosage of pharmaceutical composition for preparing of the gavage embodiment of the present invention 2 respectively; Positive controls gavage Qianlieshu pill (Beijing Kangdini Pharmaceutical Co., Ltd. produce, the accurate word Z10910009 of traditional Chinese medicines), dosage in table 1, every day 1 time.Except blank group rat, the prostate siphonal lobe internal lobe of each group rat injects 1.5 × 107/ml colon bacillus bacterium liquid 0.1ml, and blank group injects the normal saline of sterilizing, and continuous gastric infusion amounts to 25 days.After last administration 30min, put to death each treated animal, win prostate, massotherapy gets 10 μ l prostatic fluid, counts leukocyte count under the microscope, separately gets prostatic fluid smear, Microscopic observation lecithin density.Experimental result is in table 3, table 4.
Table 3 pharmaceutical composition of the present invention is on the impact of bacterial prostatitis model rat leukocyte sum
Note: compare with blank group,
#p<0.05,
##p<0.01; Compare with model group,
△ p<0.05,
△ △ p<0.01, compares with positive controls, * P<0.05, * * P<0.05.
Table 4 pharmaceutical composition of the present invention is on the impact of the lecithin density of bacterial prostatitis
Note: compare with blank group,
#p<0.05,
##p<0.01; Compare with model group,
△ p<0.05,
△ △ p<0.01, compares with positive controls, * P<0.05.
As can be seen from Table 3, contrast with model group, the rat leukocyte sum of the high, medium and low dosage group of pharmaceutical composition of the present invention significantly reduces, and has the change (P<0.01) of pole significance; High dose group and low dose group have the change (P<0.05) of significance compared with positive controls.
As can be seen from Table 4, contrast with model group, the lecithin density of the prostatitis rat of the high, medium and low dosage group of pharmaceutical composition of the present invention significantly increases, and high dose group, middle dosage group and low dose group have the change (P<0.01) of pole significance compared with model group; High dose group and low dose group have the change (P<0.05) of significance compared with positive controls, illustrate that Chinese medicine composition of the present invention can effectively reduce total white blood cells and the lecithin density increased in rat prostate liquid in rat non-bacterial prostatic fluid.
3, pharmaceutical composition of the present invention is on the impact of benign prostatic hyperplasia in rats
Get healthy male Wistar rat 20, prostatitis male Wistar rat 160, body weight 150-220g, 20 healthy male Wistar rats are blank group, 160 prostatitis male Wistar rats are divided into 8 groups at random, often organizing 20, is model group, high dose 1 group, middle dosage 1 group, low dosage 1 group, high dose 2 groups, middle dosage 2 groups, low dosage 2 groups and positive controls.Except blank group 10, all extract bilateral testes for other 5 groups, after 8 days, every rat injects Testosterone Propionate 5ml/kg every day, continuous 30 days, brings out benign prostatic hyperplasia in rats.Wherein blank group, model group are to the distilled water of equivalent; High dose 1 group, middle dosage 1 group, low dosage 1 group be the high, medium and low dosage of pharmaceutical composition for preparing of the gavage embodiment of the present invention 1 respectively; High dose 2 groups, middle dosage 2 groups, low dosage 2 groups be the high, medium and low dosage of pharmaceutical composition for preparing of the gavage embodiment of the present invention 2 respectively; Positive controls gavage Qianlieshu pill (Beijing Kangdini Pharmaceutical Co., Ltd. produces, the accurate word Z10910009 of traditional Chinese medicines), dosage is in table 5, every day 1 time, successive administration, after 30 days, puts to death rat, extract bilateral prostate siphonal lobe to weigh, calculate prostate weight in wet base coefficient.Experimental result is as table 5.
Table 5 pharmaceutical composition of the present invention is on the impact of benign prostatic hyperplasia in rats body of gland weight in wet base coefficient
Note: compare with blank group,
#p<0.05,
##p<0.01; Compare with model group,
△ p<0.05,
△ △ p<0.01, compares with positive controls, * P<0.05.
As can be seen from Table 5, contrast with model group, the body of gland weight in wet base coefficient of the high, medium and low dosage group of pharmaceutical composition of the present invention significantly reduces, and high dose group, middle dosage group and low dose group have the change (P<0.01) of pole significance compared with model group.High dose group and middle dosage group have the change (P<0.05) of significance compared with positive controls, show that pharmaceutical composition of the present invention has obvious inhibitory action to benign prostatic hyperplasia in rats caused by Testosterone Propionate.
Above content is in conjunction with concrete preferred implementation further description made for the present invention, can not assert that specific embodiment of the invention is confined to these explanations.For general technical staff of the technical field of the invention, without departing from the inventive concept of the premise, some simple deduction or replace can also be made, all should be considered as belonging to protection scope of the present invention.
Claims (5)
1. the prostatitic pharmaceutical composition for the treatment of, it is characterized in that, described pharmaceutical composition is made up of the raw material of following parts by weight: Folium Artemisiae Argyi 10-25 part, Radix Astragali 9-20 part, Cortex Phellodendri 8-15 part, Radix Rehmanniae 8-15 part, Fructus Kochiae 3-10 part, Rhizoma Smilacis Glabrae 6-12 part, Coriolous Dersicolor (Fr.) Quel 6-12 part, Caulis Akebiae 3-8 part, Herba Plantaginis 3-6 part, Rhizoma Dioscoreae 2-6 part and Radix Glycyrrhizae 1-10 part.
2. the prostatitic pharmaceutical composition for the treatment of as claimed in claim 1, it is characterized in that, described pharmaceutical composition is made up of the raw material of following parts by weight: Folium Artemisiae Argyi 10 parts, the Radix Astragali 9 parts, Cortex Phellodendri 8 parts, Radix Rehmanniae 8 parts, the Fructus Kochiae 3 parts, Rhizoma Smilacis Glabrae 6 parts, Coriolous Dersicolor (Fr.) Quel 6 parts, Caulis Akebiae 3 parts, Herba Plantaginis 3 parts, Rhizoma Dioscoreae 2 parts and 1 part, Radix Glycyrrhizae.
3. the prostatitic pharmaceutical composition for the treatment of as claimed in claim 1, it is characterized in that, described pharmaceutical composition is made up of the raw material of following parts by weight: Folium Artemisiae Argyi 20 parts, the Radix Astragali 15 parts, Cortex Phellodendri 12 parts, Radix Rehmanniae 12 parts, the Fructus Kochiae 6 parts, Rhizoma Smilacis Glabrae 9 parts, Coriolous Dersicolor (Fr.) Quel 9 parts, Caulis Akebiae 6 parts, Herba Plantaginis 4 parts, Rhizoma Dioscoreae 4 parts and 5 parts, Radix Glycyrrhizae.
4. the prostatitic pharmaceutical composition for the treatment of as claimed in claim 1, it is characterized in that, described pharmaceutical composition is made up of the raw material of following parts by weight: Folium Artemisiae Argyi 25 parts, the Radix Astragali 20 parts, Cortex Phellodendri 15 parts, Radix Rehmanniae 15 parts, the Fructus Kochiae 10 parts, Rhizoma Smilacis Glabrae 12 parts, Coriolous Dersicolor (Fr.) Quel 12 parts, Caulis Akebiae 8 parts, Herba Plantaginis 6 parts, Rhizoma Dioscoreae 6 parts and 10 parts, Radix Glycyrrhizae.
5. the prostatitic pharmaceutical composition of the treatment as described in any one of claim 1-4, is characterized in that: described pharmaceutical composition is made into capsule, tablet, powder or granule.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510988911.4A CN105412511A (en) | 2015-12-28 | 2015-12-28 | Medicine composition for treating prostatitis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510988911.4A CN105412511A (en) | 2015-12-28 | 2015-12-28 | Medicine composition for treating prostatitis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105412511A true CN105412511A (en) | 2016-03-23 |
Family
ID=55491358
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510988911.4A Withdrawn CN105412511A (en) | 2015-12-28 | 2015-12-28 | Medicine composition for treating prostatitis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105412511A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105770552A (en) * | 2016-04-12 | 2016-07-20 | 广州三得医疗科技有限公司 | Chinese herba preparation containing folium artemisiae argyi and used for treating prostatitis and preparing method thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101406605A (en) * | 2008-09-03 | 2009-04-15 | 牛志刚 | Granule for treating prostatitis containing six ingredients |
-
2015
- 2015-12-28 CN CN201510988911.4A patent/CN105412511A/en not_active Withdrawn
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101406605A (en) * | 2008-09-03 | 2009-04-15 | 牛志刚 | Granule for treating prostatitis containing six ingredients |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105770552A (en) * | 2016-04-12 | 2016-07-20 | 广州三得医疗科技有限公司 | Chinese herba preparation containing folium artemisiae argyi and used for treating prostatitis and preparing method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102846866B (en) | Chinese medicine composition for prevention and control of porcine circovirus disease and preparation method thereof | |
| CN102114180B (en) | Chinese medicinal oral decoction for treating chronic pharyngitis | |
| CN101007140A (en) | A proprietary Chinese medicine for treating chronic pharyngitis | |
| CN103301267A (en) | Traditional Chinese medicine composition for treating hypertension and/or atherosclerosis and application thereof | |
| CN104840695A (en) | Medicine combination for treating white scour of piglet and preparation method thereof | |
| CN105943963A (en) | Medicine for treating pig pneumonia | |
| CN102370852A (en) | Chinese herbal medicine for treating chronic colitis | |
| CN105056104A (en) | Traditional Chinese medicine for treating hepatitis | |
| CN105412511A (en) | Medicine composition for treating prostatitis | |
| CN104800626A (en) | Preparation method for medicine for treating renal failure | |
| CN105327103A (en) | Medicine composition for treating rhinitis and nasosinusitis and preparation method of medicine composition | |
| CN105412621A (en) | Method for preparing pharmaceutical composition for treating hemorrhoids | |
| CN101549140B (en) | Traditional Chinese medicine composition for treating AIDS and preparation method thereof | |
| CN105435017A (en) | Method for preparing pharmaceutical composition for treating prostatitis | |
| CN104800772A (en) | Traditional Chinese medicine composition for treating vital-energy-depression type coronary heart disease and application of traditional Chinese medicine composition | |
| CN104606600A (en) | Traditional Chinese medicine composition for treating interstitial lung disease and preparation method of composition | |
| CN104623532A (en) | Traditional Chinese medicine composition for treating glioma and preparation method thereof | |
| CN104645247B (en) | A kind of Chinese medicine preparation for treating hepatolenticular degeneration and preparation method thereof | |
| CN105597011A (en) | Method for preparing traditional Chinese medicine composition for treating acute or chronic rhinitis | |
| CN105456447A (en) | Folium artemisiae argyi-containing traditional Chinese medicine composition with function of promoting blood circulation to remove stasis and preparation method thereof | |
| CN105770515A (en) | Traditional Chinese medicinal composition for treating prostatitis and preparation method of traditional Chinese medicinal composition | |
| CN108498649B (en) | Scorpion-astragalus root ointment | |
| CN101884677A (en) | Chinese medicinal composition for treating stasis acute appendicitis | |
| CN106039075A (en) | Traditional Chinese medicine composition and method for treating lung and stomach heat accumulated type chronic pharyngitis | |
| CN105412392A (en) | Traditional Chinese medicinal composition for treating hemorrhoids and preparation method of traditional Chinese medicinal composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20160323 |